Immune checkpoint inhibitors related cardiovascular toxicity: 3‑mounth follow-up

Aim. To analyze the condition of the cardiovascular system in oncological patients receiving immune antitumor therapy with immune checkpoint inhibitors (CPIs) based on results of laboratory and instrumental examinations during a 3-month follow-up.

Material and methods. This multicenter prospective observational study included 49 patients (25 men and 24 women aged 65.6±8.7 and 64.3±9.6 years, respectively). A laboratory screening (C-reactive proteins, troponin I, N-terminal pro-brain natriuretic peptide), EchoCG, and carotid ultrasound were performed for all patients. 27 patients were followed up at 3 months after the antitumor therapy initiation. Statistical analysis was performed with the StatPlus 8.0.3 software.

Results. Incidence of cardiovascular complications was 16.3 %. The following significant changes in EchoCG parameters were observed: LV EF; (p=0.017), increased LV end-systolic volume (ESV) (р=0.023), and increased LV index of myocardial performance (LIMP; р=0.016). The degree of changes in ESV (ΔESV) depended on a history of chronic heart failure (р=0.03), whereas the degree of changes in EF (ΔEF) depended on the patient’s age at the initiation of antitumor therapy (р=0.006). Ultrasound showed an increase in maximum carotid stenosis (р=0.018).

Conclusion. The study showed a high incidence of newly developed cardiovascular complications associated with the CPI treatment as well as the presence of changes in EchoCG parameters and data of carotid ultrasound.

1. Kushnareva E.A., Gavrilyuk N.D., Shuginova T.N., Moiseeva O.M. Immune checkpoint inhibitor-induced myocarditis. Russian Journal for Personalized Medicine. 2022;2(4):35–43. DOI: 10.18705/2782-3806-2022-2-4-35-43

2. Orlova K.V., Fedyanin M.Yu., Simanenkov K.E., Dergunov A.S., Goldshmidt P.R., Saydullaeva A.F. et al. Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study. Journal of Modern Oncology. 2022;24(4):413–25. DOI: 10.26442/18151434.2022.4.202035

3. Robert C, Ribas A, Schachter J, Arance A, Grob J-J, Mortier L et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The Lancet Oncology. 2019;20(9):1239–51. DOI: 10.1016/S1470-2045(19)30388-2

4. Kudo M. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition. 2022;11(4):592–6. DOI: 10.21037/hbsn-22-143

5. Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New England Journal of Medicine. 2022;386(1):24–34. DOI: 10.1056/NEJMoa2109970

6. O’Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A et al. Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. Journal of Clinical Oncology. 2022;40(7):752–61. DOI: 10.1200/JCO.21.01874

7. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine. 2022;386(21):1973–85. DOI: 10.1056/NEJMoa2202170

8. Kushnareva E.A., Moiseeva O.M. Immune checkpoint inhibitor myo- carditis: a systematic case study. Russian Journal of Cardiology. 2020;25(11):185–91. DOI: 10.15829/1560-4071-2020-3910

9. Inno A, Maurea N, Metro G, Carbone A, Russo A, Gori S. Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. Cancer Immunology, Immunotherapy. 2021;70(10):3041–53. DOI: 10.1007/s00262-021-02938-z

10. Salem J-E, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. The Lancet Oncology. 2018;19(12):1579–89. DOI: 10.1016/S1470-2045(18)30608-9

11. Oren O, Yang EH, Molina JR, Bailey KR, Blumenthal RS, Kopecky SL. Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. The American Journal of Cardiology. 2020;125(12):1920–6. DOI: 10.1016/j.amjcard.2020.02.016

12. Jain P, Gutierrez Bugarin J, Guha A, Jain C, Patil N, Shen T et al. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open. 2021;6(5):100252. DOI: 10.1016/j.esmoop.2021.100252

13. Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK et al. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020;142(24):2299– 311. DOI: 10.1161/CIRCULATIONAHA.120.049981

14. Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V et al. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology. 2020;6(4):519–27. DOI: 10.1001/jamaoncol.2019.5570

15. Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S et al. Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer. JAMA Oncology. 2019;5(7):1043–7. DOI: 10.1001/jamaoncol.2019.0402

16. Axelrod ML, Meijers WC, Screever EM, Qin J, Carroll MG, Sun X et al. T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature. 2022;611(7937):818–26. DOI: 10.1038/s41586-022-05432-3

17. Lucas JA, Menke J, Rabacal WA, Schoen FJ, Sharpe AH, Kelley VR. Programmed Death Ligand 1 Regulates a Critical Checkpoint for Autoimmune Myocarditis and Pneumonitis in MRL Mice. The Journal of Immunology. 2008;181(4):2513–21. DOI: 10.4049/jimmunol.181.4.2513

18. Kushnareva E, Kushnarev V, Artemyeva A, Mitrofanova L, Moiseeva O. Myocardial PD-L1 Expression in Patients With Ischemic and Non-ischemic Heart Failure. Frontiers in Cardiovascular Medicine. 2022;8:759972. DOI: 10.3389/fcvm.2021.759972

19. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244

20. Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology. 2018;71(16):1755–64. DOI: 10.1016/j.jacc.2018.02.037

21. Noseda R, Ruinelli L, Van Der Gaag LC, Ceschi A. Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study. Cancers. 2020;12(11):3480. DOI: 10.3390/cancers12113480

22. Solinas C, Saba L, Sganzerla P, Petrelli F. Venous and arterial thromboembolic events with immune checkpoint inhibitors: A systematic review. Thrombosis Research. 2020;196:444–53. DOI: 10.1016/j.thromres.2020.09.038

23. Vasyuk Yu.A., Gendlin G.E., Emelina E.I., Shupenina E.Yu., Ballyuzek M.F., Barinova I.V. et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology. 2021;26(9):152–233. DOI: 10.15829/1560-4071-2021-4703

24. Waissengein B, Abu Ata B, Merimsky O, Shamai S, Wolf I, Arnold JH et al. The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitors. Clinical Research in Cardiology. 2023;112(3):409–18. DOI: 10.1007/s00392-022-02118-8

25. Vasyuk Yu.A., Nesvetov V.V., Shkolnik E.L., Fursov S.A., Shkolnik L.D., Gendlin G.E. et al. Possibilities of modern echocardiographic technologies in the early diagnosis of the cardiotoxic effect of chemotherapy drugs anthracycline series in cancer patients. Kardiologiia. 2017;57(S4):31–7. DOI: 10.18087/cardio.2417

26. Avila MS, Ayub-Ferreira SM, De Barros Wanderley MR, Das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity. Journal of the American College of Cardiology. 2018;71(20):2281–90. DOI: 10.1016/j.jacc.2018.02.049

27. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM et al. Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies. Journal of the American College of Cardiology. 2013;61(23):2355–62. DOI: 10.1016/j.jacc.2013.02.072

28. Brumberger ZL, Branch ME, Klein MW, Seals A, Shapiro MD, Vasu S. Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardio-Oncology. 2022;8(1):3. DOI: 10.1186/s40959-022-00130-5

29. Chen X, Jiang A, Zhang R, Fu X, Liu N, Shi C et al. Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis. Frontiers in Cardiovascular Medicine. 2022;9:882167. DOI: 10.3389/fcvm.2022.882167

30. Ayhan SS, Özdemir K, Kayrak M, Bacaksiz A, Vatankulu MA, Eren Ö et al. The evaluation of doxorubicin-induced cardiotoxicity: Comparison of Doppler and tissue Doppler-derived myocardial performance index. Cardiology Journal. 2012;19(4):363–8. DOI: 10.5603/CJ.2012.0066

31. Moslehi JJ, Salem J-E, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet. 2018;391(10124):933. DOI: 10.1016/S0140-6736(18)30533-6

32. Liu S-Y, Huang W-C, Yeh H-I, Ko C-C, Shieh H-R, Hung C-L et al. Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity – From Case Report to Mouse Model Validation. Cancers. 2019;11(4):580. DOI: 10.3390/cancers11040580